Chronic Lymphocytic Leukemia

被引:35
|
作者
Chiorazzi, Nicholas [1 ]
Chen, Shih-Shih [1 ]
Rai, Kanti R. [2 ]
机构
[1] Northwell Hlth, Feinstein Inst Med Res, Manhasset, NY 11030 USA
[2] Donald & Barbara Zucker Sch Med Hofstra Northwell, Hempstead, NY 11549 USA
来源
关键词
B-CELL LYMPHOCYTOSIS; INDUCED CYTIDINE DEAMINASE; MINIMAL RESIDUAL DISEASE; CLASS SWITCH RECOMBINATION; CHERNOBYL CLEANUP WORKERS; BRUTONS TYROSINE KINASE; GENOME-WIDE ASSOCIATION; PREVIOUSLY UNTREATED PATIENTS; PROGRESSION-FREE SURVIVAL; CXCR4 CHEMOKINE RECEPTOR;
D O I
10.1101/cshperspect.a035220
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Patients with chronic lymphocytic leukemia can be divided into three categories: those who are minimally affected by the problem, often never requiring therapy; those that initially follow an indolent course but subsequently progress and require therapy; and those that from the point of diagnosis exhibit an aggressive disease necessitating treatment. Likewise, such patients pass through three phases: development of the disease, diagnosis, and need for therapy. Finally, the leukemic clones of all patients appear to require continuous input from the exterior, most often through membrane receptors, to allow them to survive and grow. This review is presented according to the temporal course that the disease follows, focusing on those external influences from the tissue microenvironment (TME) that support the time lines as well as those internal influences that are inherited or develop as genetic and epigenetic changes occurring over the time line. Regarding the former, special emphasis is placed on the input provided via the B-cell receptor for antigen and the C-X-C-motif chemokine receptor-4 and the therapeutic agents that block these inputs. Regarding the latter, prominence is laid upon inherited susceptibility genes and the genetic and epigenetic abnormalities that lead to the developmental and progression of the disease.
引用
收藏
页码:1 / 35
页数:35
相关论文
共 50 条
  • [1] A COMPARISON OF CHRONIC LEUKEMIC LYMPHOCYTIC LEUKEMIA, CHRONIC SUBLEUKEMIC LYMPHOCYTIC LEUKEMIA, AND LYMPHOCYTIC SARCOMA
    BIGLEY, RH
    KOLER, RD
    PIROFSKY, B
    OSGOOD, EE
    CANCER CHEMOTHERAPY REPORTS, 1962, (16): : 231 - 234
  • [2] Chronic myeloid leukemia and chronic lymphocytic leukemia
    Gore, Jill M.
    JAAPA-JOURNAL OF THE AMERICAN ACADEMY OF PHYSICIAN ASSISTANTS, 2014, 27 (02): : 45 - 46
  • [3] Chronic lymphocytic leukemia
    Hanzlik, H
    NEW ENGLAND JOURNAL OF MEDICINE, 1996, 334 (07): : 472 - 472
  • [4] Chronic lymphocytic Leukemia
    Bergmann, Manuela
    Wendtner, Clemens-Martin
    DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 2015, 140 (07)
  • [5] Chronic lymphocytic leukemia
    Angel Hernandez, Jose
    Gonzalez, Marcos
    Maria Hernandez, Jesus
    MEDICINA CLINICA, 2010, 135 (04): : 172 - 178
  • [6] Chronic lymphocytic leukemia
    Gauthier, M.
    REVUE DE MEDECINE INTERNE, 2022, 43 (06): : 356 - 364
  • [7] Chronic lymphocytic leukemia
    Jacque, Nathalie
    Leblond, Veronique
    PRESSE MEDICALE, 2019, 48 (7-8): : 807 - 815
  • [8] Chronic lymphocytic leukemia
    Ghia, Paolo
    Ferreri, Andres J. M.
    Caligaris-Cappio, Federico
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2007, 64 (03) : 234 - 245
  • [9] Chronic lymphocytic leukemia
    Munir, Talha
    Hematology, 2015, 20 (04) : 245 - 246
  • [10] Chronic lymphocytic leukemia
    Leporrier, Michel
    HEMATOLOGIE, 2007, 13 : 4 - 8